Ashish Kacholia portfolio: Fineotex Chemical share price bottomed out, may rise 25% in next 3 months, say analysts | Stock Market News
A small-cap stock of ace investor Ashish Kacholia portfolio looks poised for a healthy double-digit growth in the short term, according to market experts.
Fineotex Chemical share price, which has been under pressure for the last three consecutive months, has come under the radar of analysts. Some of them expect the stock to rise almost 5 per cent in the next three months.
The small-cap stock declined 2 per cent in intraday trade on Wednesday, December 19, amid weak market sentiment.
Ashish Kacholia portfolio stock
According to the company’s shareholding pattern data on BSE, Ashish Kacholia held as many as 31,35,568 shares of the company, equivalent to 2.74 stake, by the end of the September quarter of the current financial year.
Among the institutional investors, Nippon Life India Trustee Ltd., with account Nippon India Small Cap Fund held 40,41,828 shares, or 3.53 per cent stake, in the company by the end of the September quarter.
Fineotex Chemical share price has been under pressure this year. By December 18, the stock had lost 6 per cent in the current calendar year.
The small-cap stock hit a 52-week high of ₹458 on February 19 and a 52-week low of ₹305.20 on June 4 this year on the BSE.
On a monthly scale, it is down for the last three consecutive months. It is down over 3 per cent in December so far after a 6 per cent fall in November and an 8 per cent fall in October.
Experts expect a revival
According to Ganesh Dongre, senior manager of technical research at brokerage firm Anand Rathi, Fineotexh Chemicals shares are looking strong on the daily and weekly charts.
“The chemical stock has made a trend reversal after bottoming out at ₹320 and looks set to touch ₹380 in the near term. Those with a little long view can hold the stock for a three-month target of ₹420. However, one must maintain strict stop loss while taking any position in this Ashish Kacholia portfolio stock,” said Dongre.
Read all market-related news here
Disclaimer: The views and recommendations above are those of individual analysts, experts, and brokerage firms, not Mint. We advise investors to consult certified experts before making any investment decisions.
